These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17408841)

  • 21. Role of endogenous interferon and LPS in the immunomodulatory effects of bovine lactoferrin in murine peritoneal macrophages.
    Puddu P; Carollo MG; Belardelli F; Valenti P; Gessani S
    J Leukoc Biol; 2007 Aug; 82(2):347-53. PubMed ID: 17475783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Type I interferon in neurological disease-the devil from within.
    Hofer MJ; Campbell IL
    Cytokine Growth Factor Rev; 2013 Jun; 24(3):257-67. PubMed ID: 23548179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of type I interferons in non-viral infections.
    Bogdan C; Mattner J; Schleicher U
    Immunol Rev; 2004 Dec; 202():33-48. PubMed ID: 15546384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IFN-{beta} signaling positively regulates tumorigenesis in aggressive fibromatosis, potentially by modulating mesenchymal progenitors.
    Tjandra SS; Hsu C; Goh YI; Gurung A; Poon R; Nadesan P; Alman BA
    Cancer Res; 2007 Aug; 67(15):7124-31. PubMed ID: 17671179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular stress response in the CNS of mice after systemic exposure to interferon-alpha, ionizing radiation and ketamine.
    Lowe XR; Marchetti F; Lu X; Wyrobek AJ
    Neurotoxicology; 2009 Mar; 30(2):261-8. PubMed ID: 19162068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delivery of interferon-beta to the monkey nervous system following intranasal administration.
    Thorne RG; Hanson LR; Ross TM; Tung D; Frey WH
    Neuroscience; 2008 Mar; 152(3):785-97. PubMed ID: 18304744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human primary immunodeficiencies of type I interferons.
    Jouanguy E; Zhang SY; Chapgier A; Sancho-Shimizu V; Puel A; Picard C; Boisson-Dupuis S; Abel L; Casanova JL
    Biochimie; 2007; 89(6-7):878-83. PubMed ID: 17561326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Involvement of the Gab2 scaffolding adapter in type I interferon signalling.
    Baychelier F; Nardeux PC; Cajean-Feroldi C; Ermonval M; Guymarho J; Tovey MG; Eid P
    Cell Signal; 2007 Oct; 19(10):2080-7. PubMed ID: 17604604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon-alpha therapy does not modulate hepatic expression of classical type I interferon inducible genes.
    Meier V; Mihm S; Ramadori G
    J Med Virol; 2008 Nov; 80(11):1912-8. PubMed ID: 18814253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Poly (I:C) induced immune response in lymphoid tissues involves three sequential waves of type I IFN expression.
    Démoulins T; Baron ML; Kettaf N; Abdallah A; Sharif-Askari E; Sékaly RP
    Virology; 2009 Apr; 386(2):225-36. PubMed ID: 19232663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New insights into the evolution of IFNs: zebrafish group II IFNs induce a rapid and transient expression of IFN-dependent genes and display powerful antiviral activities.
    López-Muñoz A; Roca FJ; Meseguer J; Mulero V
    J Immunol; 2009 Mar; 182(6):3440-9. PubMed ID: 19265122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Type I IFNs and their role in the development of autoimmune diseases.
    Burdick LM; Somani N; Somani AK
    Expert Opin Drug Saf; 2009 Jul; 8(4):459-72. PubMed ID: 19548860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Limited trafficking of a neurotropic virus through inefficient retrograde axonal transport and the type I interferon response.
    Lancaster KZ; Pfeiffer JK
    PLoS Pathog; 2010 Mar; 6(3):e1000791. PubMed ID: 20221252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of murine interferon regulatory factor gene expression in the central nervous system determined by multiprobe RNase protection assay.
    Ousman SS; Campbell IL
    Methods Mol Med; 2005; 116():115-34. PubMed ID: 16000858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The yin and yang of type I interferon activity in bacterial infection.
    Decker T; Müller M; Stockinger S
    Nat Rev Immunol; 2005 Sep; 5(9):675-87. PubMed ID: 16110316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical detection of the type I interferon receptor in human fetal, adult, and neoplastic tissues.
    Navarro S; Colamonici OR; Llombart-Bosch A
    Mod Pathol; 1996 Feb; 9(2):150-6. PubMed ID: 8657722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct antiviral activities of IFN-α subtypes.
    Gibbert K; Dittmer U
    Immunotherapy; 2011 Jul; 3(7):813-6. PubMed ID: 21751948
    [No Abstract]   [Full Text] [Related]  

  • 38. Multifaceted activities of type I interferon are revealed by a receptor antagonist.
    Levin D; Schneider WM; Hoffmann HH; Yarden G; Busetto AG; Manor O; Sharma N; Rice CM; Schreiber G
    Sci Signal; 2014 May; 7(327):ra50. PubMed ID: 24866020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferons in the central nervous system: a few instruments play many tunes.
    Owens T; Khorooshi R; Wlodarczyk A; Asgari N
    Glia; 2014 Mar; 62(3):339-55. PubMed ID: 24588027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes.
    Licinio J; Kling MA; Hauser P
    Semin Oncol; 1998 Feb; 25(1 Suppl 1):30-8. PubMed ID: 9482538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.